

1 **Title**

2 Complex Foot Infection Treated with Surgical Debridement and Antibiotic Loaded
3 Calcium Sulfate - A Retrospective Cohort Study of 137 Cases.

4

5 **Abstract**

6 Complex foot infections involving bone and soft tissue in patients with co-morbidities
7 such as diabetes and peripheral arterial disease (PAD) are a cause of significant
8 hospital admission. They are associated with substantial economic costs to health
9 services worldwide. Historically, severe foot infection has been treated with surgical
10 debridement and prolonged courses of systemic antibiotics. Prolonged systemic
11 antibiotic use increases the risk of drug side effects, antimicrobial resistance and
12 Clostridium difficile infection. The purpose of this study was to investigate whether
13 surgical debridement and implantation of antibiotic loaded calcium sulfate is effective in
14 the resolution of foot infection and wound healing. A retrospective cohort study of 137
15 consecutive cases of osteomyelitis (127) or significant soft tissue infection (10) over 62
16 months from 02/2013 – 04/2018 was conducted following local ethical approval. All
17 cases of infection were treated with surgical debridement and local antibiotic-loaded
18 calcium sulfate. The primary outcomes of infection resolution, time to healing and
19 duration of post-operative antibiotics were measured. In 137 cases, 88.3 % of infections
20 resolved. Infection was eradicated in 22 patients without post-operative systemic
21 antibiotics. 82.5% of wounds healed, with an average healing time of 11.3 weeks.
22 Healing time was significantly increased for the co-morbidities of diabetes and PAD

23 (p=<0.05) and for those requiring prolonged systemic postoperative antibiotics.
24 Conservative surgical debridement and implantation of local antibiotic impregnated
25 calcium sulfate is safe and effective in managing complex foot infections. We advocate
26 early surgical intervention before deeper tissue involvement to help preserve lower limb
27 structure and function.

28

29

30 **Key words:**

31 diabetes, foot ulceration, local antibiotics, osteomyelitis, peripheral arterial disease

32

33 **Level of Clinical Evidence:**

34 3

35

36 **Introduction**

37 Worldwide diabetic foot ulceration prevalence is estimated at 6.3%; ranging from 3% in
38 Oceania to 13% in North America (1) with foot ulcers developing in 9.1-26.1 million
39 people with diabetes annually around the world (2). Fifty percent of these ulcerations
40 become infected, resulting in high rates of hospitalization, increased morbidity and
41 potential lower limb amputation (3) with mortality rates at 70% within five years of
42 below-knee amputation (2).

43

44 Diabetic foot infection (DFI) particularly osteomyelitis (OM) is difficult to treat due
45 to multidrug resistance and poor penetration of antibiotics into bone (4). There is no
46 agreed treatment strategy and the role of antimicrobial therapy and surgery is not
47 sufficiently clarified (5). Relying on systemic antibiotics for complex lower limb infection
48 can often lead to prolonged treatment that is often ineffective (6) for multiple reasons,
49 including resistance, formation of biofilms (7) and circulatory impairment (8). Systemic
50 antibiotics are also associated with adverse events (7,9,10) including liver and renal
51 impairment (11) and increased incidence of Clostridium difficile, the leading cause of
52 health-care associated infective diarrhea (12).

53

54 The use of local antibiotic delivery systems have become much more common
55 practice over recent years (4) as successfully demonstrated by multiple surgical centers
56 (7,8,11,13-19). The aim is to provide a high concentration of antibiotics locally, to
57 eradicate infection and subsequently aid limb preservation. This study aims to support
58 the use of this treatment option, as an adjunct or alternative to systemic antibiotics
59 alone. The study reports on 137 consecutive cases over 62 months. All cases had foot
60 infection and underwent conservative surgical debridement and local administration of
61 antibiotic loaded calcium sulfate (ALCS) (Stimulan Rapid Cure®, Biocomposites, Keele,
62 UK) with or without additional postoperative systemic antibiotics. Stimulan Rapid Cure®
63 is approved as a carrier for antibiotics, for use in infected bone and soft tissue voids.

64

65 Calcium sulfate (CS) belongs to a synthetic ceramic group of bone graft
66 substitutes (18) shown to be biocompatible and biodegradable (6). It is indicated for
67 bone and soft tissue infections (20) although different calcium sulfate products have
68 different approvals. The purity of medical grade CS ensures predictable in-vitro
69 dissolution after 3-4 weeks (20). Evidence for its use has been promising; Laycock et al
70 (21) demonstrated in-vitro antibiotic efficacy for 20 days using a range of antibiotics,
71 while Kanellakopoulou et al (22) noted sustained release of moxifloxacin from CS for
72 35 days in animal models with osteomyelitis. Gauland (11) meanwhile evaluated 323
73 patients who had osteomyelitis of the lower extremity and found 279 of 323 healed
74 without the need for additional intra-venous antibiotics.

75

76 The study objectives were to: determine whether conservative surgery with
77 antibiotic loaded calcium sulfate beads effectively resolved infection; healed complex
78 wounds and reduced the necessity for, or duration of, postoperative systemic
79 antibiotics. The secondary objectives were to determine comorbidities which affect
80 wound healing within the sample, and to identify adverse effects of the calcium sulfate
81 treatment strategy.

82

83

84 **Patients and Methods**

85

86 A double-center, retrospective observational cohort study was performed by medical
87 record review of all patients undergoing surgical debridement of complex foot infection,
88 over a 62 month period from 02/2013- 04/2018. Patients were recruited from two
89 hospitals under the care of one surgical team (FW, RM, AB). The medical records of
90 137 consecutive cases of complex foot infection treated with surgical debridement were
91 reviewed. All surgery was performed between February 2013 and April 2018. The
92 curtailment of date of the study was July 18th, 2018. Primary outcomes were infection
93 resolution, time to wound healing and duration of post-operative systemic antibiotics.
94 Secondary outcomes were medication side effects and comorbidities associated with
95 delayed wound healing. Permission to review notes was granted by the local UK
96 National Health Service clinical effectiveness team.

97
98 One hundred and thirty-seven consecutive patients were involved in the study, 117
99 (85.4%) males and 20 (14.6%) female; 113 (82.5%) had a diagnosis of diabetes; 24
100 (17.5%) had a diagnosis of Peripheral Arterial Disease (PAD). All cases of surgical
101 debridement with ALCS were included, no patients were excluded. The independent
102 variables of interest were: Gender and the comorbidities of diabetes and/or PAD. The
103 outcome measures of: Infection resolution (y/n), healing (y/n); time to healing (weeks),
104 postoperative systemic antibiotics treatment (y/n) and duration of postoperative
105 antibiotic treatment (weeks) were collated by the surgical team (RM,FW,AB). This was
106 achieved via the review and abstract of data from medical records, laboratory reports

107 and radiographic images (RM,FW,AB) (23). The outcomes assessors consisted of the
108 surgical team undertaking the surgical debridement (RM,FW,AB).

109

110 Complex foot infection was defined as all cases of OM or significant soft tissue infection.

111 OM was diagnosed through positive probe-to-bone test (24) and radiographic findings

112 demonstrating cortical disruption, periosteal reaction and bone destruction, or by bone

113 biopsy. Soft tissue infection (STI) was diagnosed from clinical signs, in line with the

114 Infectious Diseases Society of America (IDSA) guidelines (25) and by positive microbial

115 culture of tissue sampling. PAD was determined by the presence or absence of

116 palpable dorsalis pedis and posterior tibial pulses. Time to healing was defined as the

117 time (in weeks) taken to achieve intact skin postoperatively. Infection resolution was

118 determined by the eradication of all clinical signs and symptoms (following IDSA

119 guidelines) combined with radiological evidence of no progression of osteomyelitis.

120 Culturing wounds without clinical signs of infection has no predictive value for outcomes

121 and therefore was not utilized to determine the presence or absence of infection (26)

122

123

124 *Intervention*

125

126 All patients underwent surgical debridement as day case surgery utilizing a

127 regional ankle block. The patients were positioned supine; a pneumatic ankle

128 tourniquet was applied in all cases with the exception of those with medial vessel

129 calcification. The foot was elevated and swabbed with Iodinated Povidone and then
130 draped utilizing aseptic non-touch technique. Where a tourniquet was applied the foot
131 was then exsanguinated with a single use Esmarch bandage and the tourniquet inflated
132 to 100mmHG above systolic blood pressure. Surgical debridement was performed and
133 non-viable tissue excised. This was followed by high-volume irrigation using a 50/50 mix
134 of iodinated povidone and sodium chloride solution 0.9% of between 100 and 500 ml,
135 depending of the wound dimensions. Tissue samples were taken and sent for
136 microbiological and histological testing.

137

138 ALCS was prepared in theatre by mixing vancomycin (1 g) in powder and
139 gentamicin in liquid (3 ml/120 mg) with 5 cm³ of calcium sulfate hemihydrate. This was
140 subsequently placed in a mold mat to produce multiple beads. Setting time is variable
141 dependent on the antibiotic selection (approximately 5 minutes). The synthetic
142 biocompatible material acts as a drug delivery system (15) for the antibiotic. Gentamicin
143 and vancomycin were selected for their broad spectrum characteristics, predictable and
144 rapid setting times with the carrier vehicle. Irrespective of microbiological sensitivities,
145 this combination has been shown to provide better in vivo results than empiric
146 antibiotics or those selected based on culture and sensitivity data (11). The set beads
147 were then implanted deep within the wound and the medullary cavity of resected bone
148 to enable optimum penetration. Up to 5 cm³ was implanted depending on the size of the
149 void.

150

151 When appropriate, surgical closure was achieved with 3.0 prolene sutures to
152 retain the antibiotic loaded beads. Appropriate sterile dressings were applied and the
153 patient was discharged on the same day. Postoperative review took place within 2-3
154 days (FW, RM). Some patients were immobilized in a cast to expedite postoperative
155 healing. All patients were advised to rest and elevate the affected limb for a minimum of
156 two weeks after the surgery. Twenty-two patients were discharged without systemic
157 postoperative antibiotics the remainder had antibiotics for between 2 days and 84 days,
158 (mean - 18.6 days). The decision to supply or withhold systemic antibiotics was
159 primarily dependent on the severity of the infection. Where infection was known to be
160 antibiotic resistant or with systemic involvement then oral or IV antibiotics were
161 administered in addition to the calcium sulfate implantation.

162

163

164 *Statistical Plan*

165

166 For time to healing low numbers of events precluded multiple regression
167 approaches. This outcome was modelled using a series of uncontrolled logistic
168 regression analyses and a series of uncontrolled Cox time-to-event analyses. Cases in
169 which healing was not achieved by the curtailment of the study were recorded as right-
170 censored observations, with the date of censoring set at the curtailment of the study on
171 July 18th 2018. For all models, p-values, odds/hazard ratios and associated 95%
172 confidence intervals were reported. Survival curves were constructed considering the

173 event of healing for all variables revealed to be significantly associated with the time-
174 related outcome. Whilst infection resolution Yes/No (a binary response) was recorded,
175 the exact time to infection resolution could not be established from the note review.

176

177

178 **Results**

179 Valid data was obtained between 02/2013 and 04/2018 from 137 patients. Sample
180 characteristics are summarized in Table 1. Of 137 patients infection was resolved in
181 121 (88.3%) with the remaining 16 (11.7%) unresolved or lost to follow-up. 109 patients
182 achieved healing (79.6%) and 16 (20.4%) patients did not achieve healing. The logistic
183 regression analyses revealed that in uncontrolled models, age ($p=0.036$) and post-
184 operative duration of antibiotics ($p<0.001$) were significantly associated with time to
185 healing at the 5% significance level. No other variable achieved statistical significance
186 at the 5% significance level. With no a priori hypotheses, only the postoperative duration
187 of antibiotics parameter would be considered to show significance following a correction
188 for multiple comparisons. The odds ratio of 0.999 (95% confidence interval 0.999 to
189 1.00) revealed that the odds of healing decreases by about 0.7% with each additional
190 week of antibiotic duration (3% with each additional month). Parameters of all logistic
191 regression models are given in Table 2.

192

193 The Cox time to event analyses revealed that in uncontrolled models
194 postoperative duration of antibiotics ($p=0.042$), diabetes status ($p=0.046$) and PAD

195 (p<0.001), were significantly associated with time to healing at the 5% significance level
196 (Table 3). No other variable achieved statistical significance at the 5% significance level.
197 With no a priori hypotheses, only the PAD parameter would be considered to show
198 significance following a correction for multiple comparisons. The hazard ratio of 0.329
199 (95% confidence interval 0.180 to 0.602) revealed that the “hazard” of healing in those
200 with PAD was approximately one third those with no PAD. Parameters of all models are
201 given in Table 3.

202

203 Survival curves for patients discriminated by duration of post-operative antibiotics
204 (dichotomized into up to 1 month and over 1 month), by diabetes status and by
205 presence or absence of PAD are presented in Figs. 7-9. The ungrouped survival curve
206 for healed wounds alone is presented in Fig. 10.

207

208 The proportion of unhealed ulcerations drops rapidly in all patients during the
209 initial 25 weeks, with little substantive difference between groups up to that point.
210 Beyond that point, greater levels of healing are observed in patients with postoperative
211 antibiotics up to 1 month, with no diabetes and with no PAD. However, this latter effect
212 may be a sampling artefact: low numbers of patients with PAD (n=24) and those without
213 diabetes (n=24) limits the power of the analysis.

214

215

216 **Discussion**

217 *Resolution of Infection*

218 In 137 consecutive cases of osteomyelitis (127) and soft tissue infection (10)
219 88.3 % of infections resolved and 11.7% did not or lost to follow-up. This compares
220 similarly with Kapur et al (27) where 50 patients with diabetes underwent surgical
221 debridement and antibiotic implantation for osteomyelitis of the foot, with 7 (14%)
222 patients requiring further surgery within 12 months related to their initial procedure.
223 Thus this preliminary study suggests that this is a safe and effective method in reducing
224 the need for amputation. Limitations of the study were that some patients had
225 concurrent systemic antibiotic management and some peri-operative data was not
226 available for review to allow further analysis.

227

228 Most studies into surgical debridement, combined with the use of local delivery of
229 antibiotics, utilized systemic antibiotics postoperatively (17,28,29). Our study
230 demonstrates a similar approach in many respects, with the exception that systemic
231 antibiotics were not supplied postoperatively in all cases. Twenty-two patients were
232 treated successfully for infection with ALCS but no systemic antibiotics. Patil et al (30)
233 treated 106 diabetic lower limb infected patients with ALCS and found 98 (92%) with no
234 recurrence of infection. Interestingly, only 28 (26%) received supplementary systemic
235 antibiotics. The mean follow up period however was short at 92 days and debridement
236 was described as radical. This may suggest that systemic antibiotic therapy may not be
237 required for all cases following surgical debridement and topical antibiotic treatment.

238

239 For those assessed as requiring additional systemic postoperative antibiotics, the
240 authors (RM,FW) utilized a greater proportion of oral antibiotics (58.4% patients
241 compared with IV antibiotics 24.1% patients) than in comparable studies. Of this sub-
242 set, Infection resolved in 87.5% and 87.9% which demonstrates a similar outcome. It
243 could be posited that, the route of antibiotic administration had little bearing on
244 successful infection eradication. This is supported by the findings of many previous
245 studies which back up the high bioavailability and efficacy associated with oral therapy
246 (31,32,33)

247

248 Systemic antibiotic efficacy may be limited by impaired blood flow of infected
249 bone resulting in low penetration at the infection site [8,9,10]. The study found that only
250 one patient (n=1/24) with PAD had infection which was unresolved and required further
251 debridement. This may suggest that local implantation is an important route of
252 administration for this cohort of patients, and may perhaps be a viable alternative to
253 parenteral treatment where vascularity is compromised (34).

254

255 However, it is not certain that the local implantation of antibiotics alone is
256 responsible for the eradication of infection and this may be attributed to the surgical
257 debridement. In this study, surgical debridement was conservative in nature with every
258 effort to preserve structure and function, devitalized infected tissue was excised and
259 thorough irrigation was performed significantly reducing the local bacterial burden (35).
260 Lazaro-Martinez et al (5) reaffirms this who found no significant difference in 52 patients

261 with diabetic foot osteomyelitis (DFO) as randomized into either a group receiving up to
262 90 days of systemic antibiotics or in a group undergoing surgery. Results demonstrated
263 primary healing in 75% compared to 86.3% for the antibiotic and surgery groups
264 respectively and healing achieved in 7 and 6 weeks. There was however, a short follow-
265 up period of 12 weeks and relatively low sample size.

266 It is difficult to determine specific reasons why some of our infections were not
267 eradicated, but it may be due, primarily to multi-resistant organisms and, in some cases,
268 incomplete surgical debridement.

269

270 *Healing Times and Impact of Co-morbidities*

271 Healing was defined once complete epithelialization had taken place, which
272 includes the incision line and any associated ulceration. Our results demonstrate that
273 82.5% of patients healed following surgical intervention and antibiotic packing with a
274 mean average healing time of 11.3 weeks. The remaining 17.5% episodes that did not
275 heal either required further debridement, died before the wound had healed, were lost to
276 follow-up or did not heal by the curtailment of the study of July 18th 2018. In
277 comparison with other studies, Pyho et al (36) found 14 (48%) neuropathic heel ulcers
278 healed that underwent surgery with or without some form of antibiotic bone substitute.
279 Patients with critical limb ischemia however were excluded and the follow up-period was
280 only 350 days. Wai Chon et al (29) noted 16 (84%) of patients with diabetic foot
281 ulceration undergoing debridement, lavage and administration of ALCS healed within 1
282 month. Gauland (11) found that 70% of patients healed in a group of 323 with

283 osteomyelitis of the lower extremity who underwent surgery and local antibiotic
284 implantation while Grannon and Pierides (37) noted a healing rate of 23% with a further
285 69% on a healing trajectory in a group of patients with diabetes with recalcitrant foot
286 osteomyelitis which had previously failed to heal with long courses of systemic
287 antibiotics or had relapsed. Jogia et al (38) meanwhile analyzed 109 patients with
288 diabetes and subsequently underwent local antibiotic implantation for osteomyelitis.
289 Mean average postoperative healing time was 6 weeks, although PAD was excluded
290 and all patients received systemic antibiotics and offloading. In another study, Jogia et
291 al (16) retrospectively analyzed 20 patients with diabetes over 18 months with forefoot
292 osteomyelitis. Median healing time was 5 weeks, with all patients achieving healing and
293 no episodes of recurrence within 12 months.

294

295 Healing rates and times in our study were summarized and analyzed over
296 subgroups based on antibiotic administration, with minimal difference between those
297 who had postoperative systemic antibiotics, compared to those that did not; revealing
298 no evidence for improved healing using antibiotics. However, the precision of the
299 analysis is limited by the low frequency of patients who had no postoperative antibiotics.
300 Those that had antibiotics up to one month were significantly more likely to heal than
301 those who received antibiotic administration over one month (Fig. 7); suggesting that
302 the use of prolonged antibiotics does not heal wounds. This may be because those
303 who had resistant infections may have had continued antibiotic administration and
304 therefore more likely to predispose to a poor outcome with increased healing times. It

305 may also be the case that subjects who had prolonged courses of antibiotics may have
306 had a greater propensity to an unsalvageable wound that was unlikely to heal. In a non-
307 randomized study with limited sample size it is not possible to adjust for such potential
308 confounders.

309

310 A similar consecutive retrospect study conducted by Dekker et al (39) suggested
311 ALCS may not be beneficial. They compared patients who underwent surgical
312 debridement without ALCS, to a combination of debridement and local implantation of
313 antibiotics. There was no significant difference between the two groups in healing time.
314 Similarly, in a retrospective comparative study, Qin et al (40) compared surgical
315 debridement with surgical debridement and implantation of ALCS in DFO and found no
316 improvement in the latter group in healing rate, healing time or amputation rate. It did
317 however; find that ALCS can prevent the recurrence of DFO demonstrating 0%
318 recurrence compared to 36% recurrence in the debridement group alone.

319

320 Unsurprisingly, a diagnosis of diabetes also had a significant effect on healing
321 rates (Table 1); with 22 out of 24 (91.7%) non diabetes patients healing compared to 87
322 out of 113 (77%) diabetic patients. Time to healing was also found to be significantly
323 increased in those patients with diabetes and hence likely to predispose to a poorer
324 outcome (Fig. 8) although low numbers of patients with diabetes reduced the power of
325 the analysis. Tsourdi et al (41) refers to many mechanisms of the deleterious effect of
326 diabetes on wound healing, including: extrinsic factors, such as repeated mechanical

327 stress from an insensate foot due to neuropathy; as well as intrinsic factors, including
328 ischemia from micro and macrovascular disease, the direct effect of hyperglycemia on
329 collagen synthesis, and the clinical correlation of hyperglycemia and poor wound
330 healing.

331

332 Diabetes substantially increases the risk of peripheral arterial disease, with
333 vascular diseases, particularly atherosclerosis, a major cause of disability and death
334 (42). We found that those patients with PAD had poor healing rates and times. Only
335 50% of patients with PAD healed, compared to 89.8% with no PAD. Similarly, there
336 were significantly reduced levels of healing over time (Fig. 9) with overall mean healing
337 of 16.4 weeks in those with PAD compared to 10.7 weeks in patients with no PAD;
338 although data was only available for 11 patients in the vascular impairment group
339 because 50% failed to heal, requiring further debridement or amputation.

340

341

342 *Systemic Postoperative Antibiotics*

343 Systemic antibiotics have well documented disadvantages, including:
344 antimicrobial resistance and toxic effects with liver and renal impairment. These effects
345 are all too common particularly in patients who may already be susceptible to organ
346 failure; with wide-ranging cost implications arising from the cost of the drugs,
347 administration costs, blood monitoring and managing adverse effects. Finding novel
348 ways to reduce the use of systemic antibiotics is of paramount importance in future

349 management of eradicating infection and reducing antibiotic resistance (37). Our study
350 questions the absolute requirement for systemic antibiotics in all cases once surgical
351 debridement and antibiotic loaded calcium sulfate beads have been implanted for foot
352 infection. In this study 23 (16.8%) patients did not receive postoperative systemic
353 antibiotics in comparison to 114 (83.2%) patients who received IV or oral systemic
354 antibiotics for a mean average duration of 18.6 days and ranging from 1-84 days. Of this
355 latter group 22 (19.3%) patients only received them for up to 48 hours for prophylaxis.
356 Based on the findings of this and other studies, the authors question the value of short
357 postoperative courses of antibiotics due to the successful outcomes in the non-
358 postoperative antibiotic group. No data however, was available on two (1.5%) patients.
359 Fleiter et al (7) found that 13 out of 20 patients did not require concomitant systemic
360 antibiotics in a caseload of post traumatic/postoperative bone infections, with 20%
361 requiring further surgery due to recurrence of infection which the authors ascribe to
362 incomplete debridement. Jogia et al (16) found that the mean duration of postoperative
363 antibiotics for a similar cohort of patients to ours after locally administered antibiotics
364 was 14 days in a sample size of 20 patients. In another study by Jogia et al (38), a case
365 series of 109 patients received 1.4 weeks (10 days) of postoperative systemic
366 antibiotics but with a mean duration of 8 weeks preoperatively. Grannon and Pierides
367 (37) found 77% required post-operative antibiotics for a mean 7 weeks duration in
368 comparison to 82.4% in our study with a mean duration of only 18.6 days.

369

370 The majority of our patients underwent surgical debridement and local antibiotic

371 implantation for infection of bone as opposed to soft tissue infection totaling 127 out of
372 137 (92.7%) cases. This may be because many patients are often referred on to a
373 specialist team belatedly when the infection has already taken hold, crossed tissue
374 planes and infected deep tissues. On this basis, we encourage early referral to a
375 specialist team and have a low threshold for early surgical intervention and local
376 antibiotic-loaded administration, ensuring a more direct route to help preserve structure
377 and function and prevent amputation. We have also used this method for prophylaxis in
378 patients with high predilection for infection in foot surgery, which has been shown to be
379 previously effective (43).

380

381 *Adverse Effects*

382 A secondary objective was to determine any adverse effects of antibiotic loaded
383 calcium sulfate. We noted no adverse reactions including any local or systemic toxicity
384 but it was noted that dissolution of ALCS did cause some skin maceration in some
385 cases to varying degrees which may have affected healing times. However, Khansa et
386 al (44) found overall complication rates between patients packed with ALCS and those
387 that were not were similar (43.8% vs. 51.9%, $p=0.54$) in 120 stage 4 pressure ulcers but
388 there were only 16 ulcers in the ALCS group. Jogia et al (16) meanwhile noted no
389 adverse reactions in 20 patients and Patil et al (30) found none in 106 patients with
390 implantation of ALCS. Inflammatory reactions have been observed previously in the
391 literature suspected to be due to the calcium rich fluid causing transient cytotoxic effects

392 (34) but overall it has been shown to be safe [8] with no nephrotoxic or hepatotoxic
393 effects (7,22,44).

394

395 *Other Outcomes*

396 Analysis of the results highlighted other unforeseen trends which were not
397 originally sought. For example, it was noted that 113 of our patients had diabetes all of
398 which had peripheral neuropathy of varying degrees. Of interest was that all but six of
399 the remaining 24 patients in the non-diabetic group had peripheral neuropathy due to
400 other causes including spina bifida, alcoholic neuropathy or neuropathy of unknown
401 cause. Although there may have been various factors contributing to their ulceration and
402 infection such as hyperglycemia, PAD, foot deformity and social factors in these cases,
403 neuropathy was a likely major underlying contributing factor to their foot disease.

404

405 The large proportion of men in the study (85.4%) suggests a greater predilection
406 to diabetic foot disease in males than females, consistent with other studies (45,46).
407 Possible reasons include males having a much greater chance of developing peripheral
408 neuropathy, more likely to smoke and increased rates of PAD. This lower risk in females
409 has also been attributed to increased joint mobility, lower foot pressures and hormonal
410 differences which are believed to enhance neural protection (45, 46).

411

412

413 *Strengths and Limitations*

414 A significant strength of this paper was that all of the surgery was performed by
415 the same surgical team experienced in diabetic foot surgery minimizing bias and
416 allowing consistency of results.

417

418 In terms of limitations, a small proportion of the patients were lost to follow-up.
419 These patients were all located out of area and had been followed by the initial referring
420 center. Those centers were contacted to provide postoperative patient data but some
421 did not respond. In addition, we could not provide data on which patients may have had
422 preoperative systemic antibiotics and the duration of the preoperative therapy. Healing
423 times, meanwhile, may have been influenced by each patient's individual postoperative
424 regime. For example, where appropriate, some patients were casted postoperatively,
425 which has been shown to expedite healing (47,48) others were not. Eradication of
426 infection and healing times would have also been dependent on glycemic control, and it
427 would have therefore been useful to have noted HbA1c results at the time of surgery.
428 Finally, determining when the infection was eradicated would have given a wider range
429 of statistical data but this is very difficult to determine.

430

431 Further studies, particularly randomized controlled trials would be useful to
432 compare surgical debridement, thorough irrigation and use of ALCS to surgical
433 debridement and thorough irrigation alone. However, from an ethical and moral
434 perspective it could be considered a high-risk strategy when the consequences of
435 failure are possible amputation.

436

437 In conclusion, a combination of conservative surgical debridement and
438 implantation of ALCS would appear to be safe and effective in managing complex foot
439 infection, and may reduce the requirement for prolonged postoperative courses of
440 systemic antimicrobials potentially reducing the associated financial cost, adverse
441 reactions and often toxic effects of these drugs. We would advocate early surgical
442 intervention in appropriate cases, to prevent deeper tissue involvement preserving lower
443 limb structure and function. However, the literature shows contradictory low-level
444 evidence into the effectiveness of the use of ALCS. This highlights the requirement for
445 further larger scale prospective studies into the efficacy of this potentially useful
446 treatment modality.

447

448 **References**

- 449 [1] Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global Epidemiology of Diabetic
450 Foot Ulceration: A Systematic Review and Meta-analysis. *Annals of Medicine*
451 49:2,106-116, 2017.
452 DOI: 10.1080/07853890.2016.1231932
- 453 [2] Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and their
454 Recurrence. *N. Engl. J. Med* 2017;376: 2367–2375, 2017.
- 455 [3] Hobizal KB, Wukich DK. Diabetic Foot Infection: Current Concept Review,
456 *Diabetic Foot & Ankle* 3, 2012. Available at:
457 <http://dx.doi.org/10.3402/dfa.v3i0.18409> Accessed June 06, 2020.
- 458 [4] Panagopoulos P, Drosos G, Maltezos E, Papanas N. Local Antibiotic Delivery
459 Systems in Diabetic Foot Osteomyelitis: Time for One Step Beyond? *The*
460 *International Journal of Lower Extremity Wounds* 14(1):87-91, 2015
- 461 [5] Lazaro-Martinez J, Aragon-Sanchez J, Garcia-Morales E. Antibiotics Versus
462 Conservative Surgery for Treating Diabetic Foot Osteomyelitis: A Randomized
463 Comparative Trial. *Diabetes Care* 37:789-795, 2014.
- 464 [6] Iannuccelli V, Coppi G, Bondi M, Pinelli M, Mingione A, Cameroni R.
465 Biodegradable Intraoperative System for Bone Infection Treatment II. *In Vivo*
466 Evaluation. *Int J Pharm* 143:187–94, 1996.

- 467 [7] Fleiter N, Walter G, Bösebeck H, Vogt S, Büchner H, Hirschberger W, Hoff-
468 Mann R. Clinical Use and Safety of a Novel Gentamicin-Releasing Resorbable
469 Bone Graft Substitute in the Treatment of Osteomyelitis/Osteitis. *Bone Joint Res*
470 3(7):223–9, 2014.
- 471 [8] Papegelopoulos PJ, Mavrogenis AF, Tsiodras S, Vlastou C, Giamarellou H,
472 Sou-cacos PN. Calcium Sulphate Delivery System with Tobramycin for the
473 Treatment of Chronic Calcaneal Osteomyelitis. *J Int Med Res* 34:704–12, 2006
- 474 [9] Wang. Y, Wang. X, Li. H, Xue. D, Shi. Z, Qi. Y, Ma. Q, Pan. Z. Assessing the
475 Character of the rhBMP-2- and Vancomycin-Loaded Calcium Sulphate
476 Composites in Vitro and in Vivo. *Arch Orthop Trauma Surg* 131, 991-1001,
477 2011.
- 478 [10] Panagopoulos. P, Tsaganos. T, Plachouras. D, Carrer. D-P, Papadopoulos.
479 A, Giamarellou. H, Kanellakopoulou. K. In Vitro Elution of Moxifloxacin and
480 Fucidic Acid by a Synthetic Crystalline Semihydrate Form of Calcium Sulphate
481 (Stimulan). *International Journal of Antimicrobial agents* 32:485-487, 2008.
- 482 [11] Gauland C. Managing Lower Extremity Osteomyelitis Locally with Surgical
483 Debridement and Synthetic Calcium Sulphate Antibiotic Tablets. *Advances in*
484 *Skin & Wound Care* 24(11):515-523, 2011.
- 485 [12] Smits WK, Lyras D, Lacy B, Wilcox MH, Kuijper EJ. *Clostridium Difficile*
486 *Infection*. *Nature Reviews Disease Primers* 2, 201620, 2016.
487 DOI: 10.1038/nrdp.2016.20
- 488 [13] Morley R, Webb. An Unusual Complication following Charcot
489 Neuroarthropathy. *Diabetic Foot Journal* 21(2):107-114, 2018.
- 490 [14] Barber A, Morley R, Webb F. Incision and Drainage of a Septic Abscess
491 following Corticosteroid Injection for Plantar Fasciitis. *Podiatry Now* 21(6):14-18,
492 2018.
- 493 [15] Morley R, Lopez F, Webb F. Calcium Sulphate as a Drug Delivery System in
494 a Deep Diabetic Foot Infection. *The Foot* 27:36-40, 2016.
- 495 [16] Jogia RM, Modha DE, Nisal K, Berrington R, Kong M-F. Use of Highly
496 Purified Synthetic Calcium Sulfate Impregnated with Antibiotics for the
497 Management of Diabetic Foot ulcers Complicated by Osteomyelitis *Diabetes*
498 *Care* 38:e79-e80, 2015.
- 499 [17] Agarwal S, Healey B. The Use of Antibiotic Impregnated Absorbable
500 Calcium Sulphate Beads in Management of Infected Joint Replacement
501 Prostheses. *JArthrosc Joint Surg* 1(2):72–5, 2014.
- 502 [18] Kumar YC, Nalini KB, Menon J, Patro DK, Banerji BH. Calcium Sulfate as
503 Bonegraft Substitute in the Treatment of Osseous Bone Defects, A Prospective
504 Study. *J Clin Diagn Res* 7(12):2926–8, 2013.
- 505 [19] Gitelis S, Brebach GT. The Treatment of Chronic Osteomyelitis with a
506 Biodegradable Antibiotic-Impregnated Implant. *Journal of Orthopaedic Surgery*
507 10(1): 53-60, 2002.
- 508 [20] Wahl P, Livio F, Jacobi M, Gautier E, Buclin. T. Systemic exposure to
509 tobramycin after local antibiotic treatment with calcium sulphate as carrier
510 material. *Arch Orthop Trauma Surg*, 131 (2011) 657–662.

511 [21] Laycock. PA, Cooper JJ, Howlin RP, Delury C, Aiken S, Stoodley P. In Vitro
512 Efficacy of Antibiotics Released from Calcium Sulfate Bone Void Filler Beads.
513 Materials 2018, 11, 2265
514 doi:10.3390/ma11112265

515 [22] Kanellakopoulou K, Galanopoulos I, Soranoglou V, Tsaganos T, Tziortzioti V,
516 Maris I, Papalois A, Giamarellou H, Giamarellos-Bourboulis J. Treatment of
517 Experimental Osteomyelitis Caused by Methicillin-Resistant
518 Staphylococcus aureus with a Synthetic Carrier of Calcium Sulphate (Stimulan)
519 Releasing Moxifloxacin. Int J Antimicrobiol Agents 33:354–9, 2009.

520 [23] Song JW, Chung KC. Observational Studies: Cohort and Case-Control
521 Studies. Plast Reconstr Surg, 126(6): 2234–2242, 2010.
522 doi:10.1097/PRS.0b013e3181f44abc.

523 [24] Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to
524 Bone in Infected Pedal Ulcers. A Clinical Sign of Underlying Osteomyelitis in
525 Diabetic patients. JAMA 273: 721-3, 1995.

526 [25] Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJG, Armstrong DG,
527 Gunner Deery H, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E.
528 Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot
529 Infections, Clinical Infectious Diseases 54(12):132–173, 2012.

530 [26] Gardner SE, Haleem A, Jao Y-L, Hillis SL, Femino JE, Phisitkul P, Heilmann
531 KP, Lehman SM, Franciscus CL. Cultures of Diabetic Foot Ulcers Without
532 Clinical Signs of Infection Do Not Predict Outcomes Diabetes Care 37(10): 2693–
533 2701, 2014.
534 doi:10.2337/dc14-0051

535 [27] Kapur B. Preserving the Diabetic Foot - Outcomes of Diabetic Foot
536 Ulceration and Osteomyelitis Treated with Antibiotic Loaded Stimulan, British
537 Orthopaedic Foot & Ankle Society Annual Scientific Meeting Sheffield, UK, 2017.

538 [28] Pierides M, Liarakos AL. Local Delivery of Antibiotics via Highly Purified
539 Calcium Sulphate Beads as an Adjunct to Surgical Debridement in the Acute
540 Management of Diabetic Foot Osteomyelitis, 15th Annual Meeting of the Diabetic
541 Foot Study Group Berlin, Germany, 2018.

542 (29) Wai Chon HT, Hamish M, Kirupananthan P, Gmati A, Abdalla H, Hicks R.
543 Stimulan® Antibiotic Impregnated Beads for the Treatment of Diabetic Foot
544 Infection. Arab J Intervent Radiol 4:73-78, 2020

545 (30) Patil P, Singh R, Agarwal A, Wadhwa R, Bal A, Vaidya S. Diabetic Foot
546 Ulcers and Osteomyelitis: Use of Biodegradable Calcium Sulfate Beads
547 Impregnated with Antibiotics for Treatment of Multi-drug Resistant Organisms.
548 Wounds 33(3):70-78, 2021

549 [31] Cunha BA. Oral Antibiotic Therapy of Serious Systemic Infections. The
550 Medical Clinics of North America 90(6):1197-1222, 2006.

551 [32] MacGregor RR, Graziani AL. Oral Administration of Antibiotics: A Rational
552 Alternative to the Parenteral Route. CID 24:457-467, 1997.

553 [33] Turnbull C, Young L, Lowery S. Oral vs. Intravenous Antibiotics for the
554 Treatment of Acute Bacterial Osteomyelitis in the Veteran Population Open
555 Forum Infectious Diseases 4:1S96, 2017. Available at:
556 <https://doi.org/10.1093/ofid/ofx163.072> Accessed June 06, 2020
557 [34] Rausschmann, M.A, Wichelhaus. T.A, Stirnal,V, Dingeldein. E, Zichner. L,
558 Schnettler. R, Alt. V. Nanocrystalline Hydroxyapatite and Calcium Sulphate as
559 Biodegradable Composite Carrier Material for Local Delivery of Antibiotics in
560 Bone Infections. *Biomaterials* 26:2677-2684, 2005.
561 [35] Tiemann AH, Hofmann GO. Wound Irrigation within the Surgical Treatment
562 of Osteomyelitis. *GMS Interdiscip Plast Reconstr Surg DGPW* 2012.
563 doi:10.3205/iprs000008
564 (36) Phyo N, Tang W, Kavarthapu V. Medium-term Outcomes of Multi-disciplinary
565 Surgical Management of Non-ischemic Diabetic Heel Ulcers. *Journal of Clinical*
566 *Orthopaedics and Trauma* 17:30-36, 2021
567 Available at: <https://doi.org/10.1016/j.jcot.2021.01.012>
568 [37] Grannon, P, Pierides M. Evaluation: Local Delivery of Antibiotics in Elective
569 Surgery to Cure Chronic Diabetic Foot Osteomyelitis and its Value to Antibiotic
570 Stewardship, 15th Annual Meeting of the Diabetic Foot Study Group, Berlin,
571 Germany, 2018.
572 [38] Jogia RJ. The Use of Locally Delivered Highly Purified Calcium Sulphate
573 Impregnated with Antibiotics in the Management of the Diabetic Foot with
574 Osteomyelitis. 15th Annual Meeting of the Diabetic Foot Study Group, Berlin,
575 Germany, 2018.
576 [39] Dekker AP, Uzoho C, Scammell B. Do Antibiotic-Impregnated Calcium
577 Sulfate Beads Improve the Healing of Neuropathic Foot Ulcers with Osteomyelitis
578 Undergoing Surgical Debridement. *Wounds* 31(6):145-150, 2019.
579 [40] Qin C-H, Zhou C-H, Song H-J, Cheng G-Y, Zhang H-A, Fang J, Tao R.
580 Infected Bone Resection Plus Adjuvant Antibiotic-Impregnated Calcium Sulfate
581 Versus Infected Bone Resection Alone in the Treatment of Diabetic Forefoot
582 Osteomyelitis. *BMC Musculoskeletal Disorders*, 20:246, 2019. Available at:
583 <https://doi.org/10.1186/s12891-019-2635-8>
584 Accessed June 06, 2020.
585 [41] Tsourdi E, Barthel A, Rietzsch H, Reichel A, Bornstein SR. Current Aspects
586 in the Pathophysiology and Treatment of Chronic Wounds in Diabetes Mellitus.
587 *Biomed Res Int*. 2013. doi:10.1155/2013/385641
588 [42] Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and Vascular
589 Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I.
590 *Circulation* 108(12):1527-32, 2003.
591 [43] Trujillo J.M, Logue ME, Kunkel R, Demas CP. Off-label Usage of Absorbable
592 Beads Containing Antibiotics for Prevention of Surgical Site Infections. *Wounds*
593 29(10):E84-E87, 2017.
594 [44] Khansa I, Barker JC, Ghatak PD, Sen CK, Gordillo GM. Use of Antibiotic
595 Impregnated Resorbable Beads Reduces Pressure Ulcer Recurrence: A
596 Retrospective Analysis. *Wound Repair Regen* 26: 221-227, 2018.

597 [45] Dinh T, Veves A. The Influence of Gender as a Risk Factor in Diabetic Foot
598 Ulceration. *Wounds* 20(5):127-31, 2008.
599 [46] Peek ME. Gender Differences in Diabetes-Related Lower Extremity
600 Amputations. *Clin Orthop Relat Res* 469(7):1951–1955, 2011.
601 doi: 10.1007/s11999-010-1735-4
602 [47] Cavanagh PR, Bus SA. Off-Loading the Diabetic Foot for Ulcer Prevention
603 and Healing. *J Vasc Surg* 52(3 Suppl): 37s–43s, 2010.
604 [48] Rogers LC, Frykberg RG, Armstrong DG, Boulton AJM, Edmonds M, Van
605 GH, Hartemann A, Game F, Jeffcoate W, Jirkovska A, Jude E, Morbach S,
606 Morrison WB, Pinzur M, Pitocco D, Sanders L, Wukich DK, Uccioli L. The
607 Charcot Foot in Diabetes. *Diabetes Care* 34(9):2123–9, 2011
608
609
610
611
612
613
614

615 **Tables**
616

Variable	Healed (n=109)	Not healed (n=28)	All cases (N=137)
Post-operative duration of antibiotics (days) (mean (SD))	17.5 (18.9)	23.9 (23.2)	18.6 (19.8)
PAD			
No PAD	97 (89.0%)	16 (57.1%)	113 (82.5%)
PAD	12 (11.0%)	12 (42.9%)	24 (17.5%)
Post-operative antibiotic delivery method			
None prescribed/no data	18 (16.5%)	5 (17.9%)	23 (16.8%)
IV	24 (22.0%)	10 (35.7%)	34 (24.8%)
Oral	67 (61.5%)	13 (46.4%)	80 (58.4%)
Gender			
Male	93 (85.3%)	24 (85.7%)	117 (85.4%)
Female	16 (14.7%)	4(14.3%)	20 (14.6%)
Age (years) (mean (SD))	60.1 (13.1)	54.3 (8.67)	60.7 (12.7)
Diabetes status			
Non-diabetic	22 (20.2%)	2 (7.1%)	24 (7.5%)
Diabetic	87 (79.8%)	26 (92.9%)	113 (92.5%)

617 **Table 1:** A statistical description of the cases
618
619
620

Variable	P-value	Odds ratio (OR)	95% CI for OR
Age	0.036	1.05	(1.00, 1.01)
Gender Male (reference) Female	0.801	1.22	(0.256, 5.84)
Diabetes status Non-diabetic (reference) Diabetic	0.234	0.284	(0.0360, 2.26)
Method of antibiotic delivery ¹ Oral (reference) IV	0.750	0.829	(0.260, 2.64)
PAD No PAD(reference) PAD	0.577	1.56	(0.330, 7.34)
Post-operative duration of antibiotics (days)	<0.001	0.999	(0.999, 1.00)

¹Analysis conducted on all cases with recorded method antibiotic delivery (n=114)

Table 2: Uncontrolled Logistic Regression Model Parameters

621
622
623
624
625
626

Variable	P-value	Hazard ratio (HR)	95% CI for HR
Age	0.959	1.00	(0.984, 1.02)
Gender Male (reference) Female	0.725	0.909	(0.553, 1.55)
Diabetes status Non-diabetic (reference) Diabetic	0.046	0.689	(0.386, 0.992)
Method of antibiotic delivery ¹ Oral (reference) IV	0.571	0.874	(0.547, 1.39)
PAD No PAD (reference) PAD	<0.001	0.329	(0.180, 0.602)

Post-operative duration of antibiotics (days)	0.042	0.988	(0.977, 1.00)
---	-------	-------	---------------

627 ¹Analysis conducted on all cases with recorded method antibiotic delivery (n=114)

628 **Table 3:** Uncontrolled Cox Regression Model Parameters

629

630

631

632 **Figure Legend/s**

633

634 **Figure 1** Preoperative Photograph of Right Foot Second Metatarsophalangeal
635 Ulceration with Underlying Osteomyelitis

636

637 **Figure 2** Preoperative X-ray of Right Forefoot in Dorsoplantar View Demonstrating
638 Second Metatarsophalangeal Joint Osteomyelitis

639

640 **Figure 3** Intraoperative Photograph Following Second Metatarsophalangeal Joint
641 Excision and Lavage with Antibiotic Loaded Calcium Sulphate Beads In situ

642

643 **Figure 4** Intraoperative Photograph following Second Metatarsophalangeal Joint
644 Excision and Lavage with Antibiotic Loaded Calcium Sulfate Following Wound Closure

645

646 **Figure 5** Six Weeks Postoperative Photograph of Plantar Aspect of Foot Following
647 Surgical Debridement and Implantation of Antibiotic Loaded Calcium Sulfate
648 Demonstrating Healed Ulceration

649

650 **Figure 6** Six Weeks Postoperative Photograph of Dorsal Healed Surgical Wound
651 Following Surgical Debridement and Implantation of Antibiotic Loaded Calcium Sulfate

652

653 **Figure 7** Survival Curve for Patients with Post-operative Antibiotics of Duration up to
654 One Month, and Over One Month

655

656 **Figure 8** Survival Curve for Patients with and without Diabetes

657

658 **Figure 9** Survival Curve for Patients with and without Peripheral Arterial Disease

659

660 **Figure 10** Survival Curve for Healed Wounds

661

662

663

664 **Funding**

665 This research did not receive any specific grant from funding agencies in the public,
666 commercial, or not-for-profit sectors.

667

668 **Declarations of interest:** none

669
670
671
672